ReCor Medical Revenue and Competitors

Location

$25M

Total Funding

Estimated Revenue & Valuation

  • ReCor Medical's estimated annual revenue is currently $82.2M per year.(i)
  • ReCor Medical's estimated revenue per employee is $313,750
  • ReCor Medical's total funding is $25M.

Employee Data

  • ReCor Medical has 262 Employees.(i)
  • ReCor Medical grew their employee count by 19% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M76-3%N/AN/A
#2
$8M32-6%N/AN/A
#3
$5M20-9%N/AN/A
#4
$8.5M346%N/AN/A
#5
$5.3M21-9%N/AN/A
#6
$49.7M1980%N/AN/A
#7
$12M48N/AN/AN/A
#8
$8.5M3421%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$56.8M181-1%$199.1MN/A
Add Company

ReCor Medical is a medical device company that designs and manufactures the Paradise® System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The System's intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States.

keywords:N/A

$25M

Total Funding

262

Number of Employees

$82.2M

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ReCor Medical News

2022-04-20 - Renal Denervation Market Research Analysis and Huge ...

... Inc., ReCor Medical, Inc., Renal Dynamics Limited ... Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6%...

2022-03-30 - ReCor Medical completes renal denervation system trial ...

Otsuka Medical Devices' subsidiary ReCor Medical has completed subject enrolment in the RADIANCE-II pivotal trial of its Paradise Ultrasound...

2022-03-30 - ReCor Medical Announces Completion of Enrollment in ...

ReCor Medical Announces Completion of Enrollment in RADIANCE-II Pivotal Trial of the Paradise™ Ultrasound Renal Denervation System for the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.1M264-2%N/A
#2
$115.7M2692%$665M
#3
$15M2698%N/A
#4
$42.6M2734%$108.5M
#5
$38.6M27610%$40M